Non-insulin oral drug(s)-Glucophage (Metformin) Posts on Medivizor
Navigation Menu

Non-insulin oral drug(s)-Glucophage (Metformin) Posts on Medivizor

Is liraglutide an effective add-on treatment for poorly controlled type 2 diabetes?

Is liraglutide an effective add-on treatment for poorly controlled type 2 diabetes?

Posted by on Aug 8, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study evaluated whether liraglutide (Victoza) improves diabetic control in patients with difficult to control type 2 diabetes (T2D) and if there were certain factors that influence the effects of liraglutide. It found that patients responded equally well to liraglutide regardless of body mass index (BMI; a measurement of...

Read More

Comparing second-line therapy options combined with metformin for patients with type 2 diabetes.

Comparing second-line therapy options combined with metformin for patients with type 2 diabetes.

Posted by on Jul 25, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study explored the effects of different second-line therapies combined with metformin (Glucophage) in patients with type 2 diabetes (T2D). The data showed that metformin combinations with a sulfonylurea (SU) had the lowest weight loss, the smallest effect of lowering blood glucose, and an overall, reduced health...

Read More

Improved outcomes with linagliptin in patients with persistent prediabetes after metformin and lifestyle modifications.

Improved outcomes with linagliptin in patients with persistent prediabetes after metformin and lifestyle modifications.

Posted by on Jun 6, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study evaluated the addition of linagliptin (Trajenta) to metformin (Glucophage) and lifestyle changes in patients with persistent prediabetes. The authors concluded that adding linagliptin after 12 months of metformin treatment and lifestyle changes improved glucose levels and pancreatic β-cell function in these...

Read More

Comparing metformin extended-release to metformin immediate-release for adults with type 2 diabetes.

Comparing metformin extended-release to metformin immediate-release for adults with type 2 diabetes.

Posted by on Jun 6, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study compared the effectiveness and tolerance of metformin (Glucophage) extended-release (MXR) and conventional metformin immediate-release (MIR) in adults with type 2 diabetes (T2D). The authors concluded that MIR had better glucose control while MXR but reduced gastrointestinal (GI) side effects. Some background...

Read More

Is treatment with pioglitazone and exenatide more effective than insulin for poorly controlled type 2 diabetes?

Is treatment with pioglitazone and exenatide more effective than insulin for poorly controlled type 2 diabetes?

Posted by on Jan 17, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study compared a combination of pioglitazone (Actos) and exenatide (Byetta) to insulin therapy for poorly controlled type 2 diabetes (T2D). It found that more patients receiving pioglitazone and exenatide achieved blood glucose control compared to those receiving insulin. Some...

Read More

Is combination treatment with exenatide and dapagliflozin safe and effective for poorly-controlled type 2 diabetes?

Is combination treatment with exenatide and dapagliflozin safe and effective for poorly-controlled type 2 diabetes?

Posted by on Dec 20, 2020 in Diabetes mellitus | 0 comments

In a nutshell This study looked at the treatment of poorly-controlled type 2 diabetics. They found that a combination of exenatide and dapagliflozin was more effective at lowering blood glucose (sugar) than either treatment alone. Some background There are many types of treatment for type 2 diabetes (T2D). Metformin (Glucophage) is commonly...

Read More

FDA Recalls

FDA Recalls

Posted by on May 31, 2020 in Blog, Diabetes mellitus | 0 comments

You may not realize it but your diabetes medication, metformin extended release, has been recalled. One of the places to look for information on recalls of medications is the Recalls, Market Withdrawals, & Safety Alerts page on the FDA website. The recall, on May 28, is for Metformin Hydrochloride Extended-Release Tablets, USP 500mg by a...

Read More

The effect of semaglutide versus sitagliptin as add-on therapy for type 2 diabetes

Posted by on Apr 13, 2019 in Diabetes mellitus | 0 comments

In a nutshell The aim of this study was to compare the effects of adding semaglutide versus sitagliptin onto metformin with or without a sulfonylurea in type 2 diabetes (T2D). The main finding was that adding 7mg or 14mg semaglutide on to metformin/sulphonylurea therapy showed greater improvements in blood sugar control compared to sitagliptin. Some...

Read More